Grifols, S.A. GRFS Archived
+0.39%This entry is more than 3 months old and has been archived. Prices reflect the last update.
✅ Key Summary
Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines. The company has reported mixed recent performance, reflecting both challenges and opportunities in the market. With a current share price of $7.61, the valuation indicates a notable basis point differential.
🏢 Company Overview
Grifols, S.A. is a leader in the biopharmaceutical industry, focusing on the research, development, and production of plasma-derived therapies. Recent earnings reports have shown a blend of revenue growth alongside increased operational costs, leading to a cautious outlook. The company's share price has experienced fluctuations, currently standing at $7.61, which suggests a significant basis point of 164389 compared to its intrinsic value. Investors are weighing the company's solid market position against broader economic pressures and competition. The company continues to invest in R&D, aiming to expand its product offerings and market reach.
📰 Related News
-
Grifols reports mixed earnings, shares fluctuateEarnings report affected investor sentiment.
-
Plasma prices increase, impacting Grifols' marginsCost pressures may influence future profitability.
-
New product line announced, aiming for market expansionPotential for revenue growth in upcoming quarters.
🏭 Competitor Comparison
-
CSL Behring CSLLYCSL Behring is a strong competitor in the plasma-derived therapies market, often leading in innovation.
-
Octapharma OCTHFOctapharma focuses on similar product lines, but with a more aggressive pricing strategy.
-
Kedrion Biopharma KEDRIKedrion offers a more niche selection of plasma products, catering to specific therapeutic areas.
📅 Grifols, S.A. discovery history
This stock has been discovered 2 times.
| Discovered | Discovery price | Current price | Return |
|---|---|---|---|
| Oct 27, 2026 | $8.10 | $8.69 | +7.28% |